Gamidov S I, Ovchinnikov R I, Popova A Yu, Avakyan A Yu, Sukhikh G T
Department of Andrology and Urology, V.I. Kulakov Research Center for Obstetrics, Gynecology and Perinatology of Minzdrav of Russia, Moscow, Russia.
Department of Obstetrics, Gynecology, Perinatology and Reproductology, I.M. Sechenov First Moscow State Medical University of Minzdrav of Russia, Moscow, Russia.
Urologiia. 2017 Jun(2 (supplement)):64-72. doi: 10.18565/urol.2017.2-supplement.64-72.
Infertility affects an estimated 15% of couples globally. Male factor infertility accounts for about a half of infertility cases. About 40% of infertile men have varicocele. The aim of this study was to investigate the efficacy and safety of a complex of acetyl-L-carnitine, L-carnitine fumarate and alpha-lipoic acid (SpermActin-forte) (SA) for adjuvant antioxidant therapy after microsurgical varicocelectomy (MVE) in men with varicocele and assess its impact on the level of DNA fragmentation in sperm cells.
This is an open, prospective, randomized trial comprising 114 men aged 25-45 (mean 34.1+/-12.1) years who underwent MVE. The patients were allocated to receive either adjuvant SA (n=38), SA in combination with a vitamin complex (VC) (n=38) or no adjuvant therapy (n=38). The efficacy was assessed at 3 months by testing standard semen parameters and the level of sperm DNA fragmentation.
MVE led to a 21.7% increase in the progressive sperm motility compared to the baseline level. In patients receiving SA, this was by 76.7% due to active sperm motility (category A) at 3 months. MVE with concurrent supplementation of SA resulted in a 22.3% decrease in the level of sperm DNA fragmentation at 3 months. When used in the postoperative period after MVE, SA and VC resulted in a 27% increase in the sperm concentration at 3 months. There were no side effects of pharmacotherapy. The statistical significance of the change in variables was calculated using the Wilcoxon test. Critical level =0.05 was established for all criteria.
Using nutraceuticals (SA) after MVE is an effective and safe adjuvant antioxidant therapy of male infertility in patients with varicocele which leads to an improvement in the basic sperm parameters (sperm concentration and motility) and a decrease in the level of sperm DNA fragmentation in the short term. Adjuvant antioxidant therapy of varicocele infertility potentiates the effects of monotherapy (both medical and surgical), leads to an increase in its effectiveness and shortens the time to pregnancy. Further studies in this field are needed to assess long-term outcomes of the treatment.
据估计,全球约15%的夫妇受到不孕不育的影响。男性因素导致的不孕不育约占不孕病例的一半。约40%的不育男性患有精索静脉曲张。本研究的目的是探讨乙酰-L-肉碱、富马酸L-肉碱和α-硫辛酸复合物(SpermActin-forte)(SA)在精索静脉曲张男性患者接受显微外科精索静脉结扎术(MVE)后辅助抗氧化治疗的疗效和安全性,并评估其对精子细胞DNA碎片化水平的影响。
这是一项开放性、前瞻性、随机试验,纳入了114名年龄在25至45岁(平均34.1±12.1岁)接受MVE的男性。患者被分配接受辅助SA治疗(n=38)、SA联合维生素复合物(VC)治疗(n=38)或不接受辅助治疗(n=38)。在3个月时通过检测标准精液参数和精子DNA碎片化水平评估疗效。
与基线水平相比,MVE使进行性精子活力提高了21.7%。在接受SA治疗的患者中,3个月时由于活跃精子活力(A类)提高了76.7%。MVE同时补充SA导致3个月时精子DNA碎片化水平降低了22.3%。在MVE术后使用SA和VC,3个月时精子浓度提高了27%。药物治疗没有副作用。使用Wilcoxon检验计算变量变化的统计学意义。所有标准的临界水平设定为0.05。
MVE后使用营养补充剂(SA)是精索静脉曲张男性患者不孕不育的一种有效且安全的辅助抗氧化治疗方法,可在短期内改善基本精子参数(精子浓度和活力)并降低精子DNA碎片化水平。精索静脉曲张不孕不育的辅助抗氧化治疗可增强单一治疗(药物和手术)的效果,提高其有效性并缩短怀孕时间。该领域需要进一步研究以评估治疗的长期效果。